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Background: Marek’s disease virus (MDV) is a highly cell-associated oncogenic α-herpesvirus that causes a disease
characterised by T-cell lymphomas. The pathogenesis, or the nature of the interaction of the virus and the host, in
the thymus are still unclear.
Results: In this study, we identified 119 differentially expressed proteins using two-dimensional electrophoresis and
mass spectrometry from the thymuses of chickens infected with the RB1B strain of MDV. These differentially
expressed proteins were found mainly at 21, 28 and 35 days post-infection. More than 20 of the differentially
expressed proteins were directly associated with immunity, apoptosis, tumour development and viral infection and
replication. Five of these proteins, ANXA1, MIF, NPM1, OP18 and VIM, were further confirmed using real-time PCR.
The functional associations and roles in oncogenesis of these proteins are discussed.
Conclusions: This work provides a proteomic profiling of host responses to MDV in the thymus of chickens and
further characterises proteins related to the mechanisms of MDV oncogenesis and pathogenesis.Background
Marek’s disease virus (MDV) is a highly cell-associated
oncogenic α-herpesvirus that leads to serious economic
losses in the poultry industry [1,2]. Marek’s disease
(MD) is a lymphoproliferative disease characterised by
immunosuppression, neurological disorders, and neo-
plastic T-cell lymphomas in chickens. MD was the first
tumour disease to be prevented by vaccination, and thus,
provides an important animal model for the study of
viral cancer development and immunity [3].
The primary target cells for MDV infection in the
chicken in vivo are B cells, then T cells, and eventually the
formation of a T-cell lymphoma occurs [4]. The mechan-
ism of lymphoma formation is very complex and has not
yet been clarified. In recent years, the dynamics of host-
protein expression in chicken immune organs have been
studied at different phases of MDV infection using two-
dimensional polyacrylamide gel electrophoresis (2-DE)* Correspondence: aijian@yzu.edu.cn
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reproduction in any medium, provided the orfollowed by the identification and characterisation of the
proteins by mass spectrometry (MS) [5-7]. In the spleens
of MDV-infected chickens, 61 protein spots representing
48 host proteins have been detected. These proteins are
involved in a variety of cellular processes, including anti-
gen processing and presentation, ubiquitin-proteasome
protein degradation (UPP), formation of the cytoskeleton,
cellular metabolism, signal transduction, and translation
regulation [5]. In the bursa of Fabricius, 24 differentially
expressed proteins associated mainly with tumour biology,
protein folding, signal transduction, immunology, cell pro-
liferation and apoptosis have been successfully identified,
and the tumour-associated proteins were significantly
increased at 14 and 21 days post-infection (dpi) [6]. Fur-
thermore, 20 proteins have been found to be differentially
expressed in the spleen when comparing MD-susceptible
B19 and MD-resistant B21 chickens [7]. These studies
have characterised the proteomic profiles of the host re-
sponse to MDV in chickens and are the basis for illustrat-
ing the mechanism of MD lymphoma formation. In
addition, Niikura et al. found that a lytic infection with
MDV up-regulates the cell surface expression of MHC
class II infected cells [8] but down-regulates theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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infected chickens [9].
The thymus is the specific organ in which the maturation
and differentiation of avian T lymphocytes take place. T-
cell immune suppression and lymphomas due to MDV in-









Figure 1 (A) The macroscopic appearance of the thymus at different
the thymus and body weight between the two groups at the different stagactivated CD4+ T lymphocytes. Morimura et al. reported
that MDV can induce apoptosis and the down-regulation of
CD8 molecules on peripheral CD4+ Tcells and the thymus,
which could contribute to immune suppression [10-12].
However, all the changes in the protein profiles that occur
after MDV infection have not been reported. Such changess MDV-infected thymus
stages of infection and in the control group. (B) The differences in
es of infection.
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and host and provide some clues to the pathogenesis of
MDV. In this study, 119 proteins that were differentially
expressed in the thymus in response to MDV infection
were identified by two-dimensional electrophoresis and
mass spectrometry techniques at 4, 7, 14, 21, 28, 35 and 42Figure 2 The analysis of the chicken thymus proteins by two-dimensi
chicken thymus at 21 dpi. The differentially expressed proteins (p ≤ 0.05 an
thymus. B. MDV-infected thymus.dpi. These proteins are associated with a wide range of bio-
logical processes, including metabolism, immunity, apop-
tosis, death, tumour development and virus infection and
replication. These proteins provide some information for
further interpretations of the pathogenesis and oncogenesis
of MDV.onal gel electrophoresis. Above images represent the proteome of
d fold change ≥ 2) are marked on the gel. A. Uninfected control
Hu et al. Virology Journal 2012, 9:256 Page 4 of 18
http://www.virologyj.com/content/9/1/256Results
Pathological changes associated with MDV infection at
different stages
The thymus of each chicken displayed severe atrophy at
21, 28 and 35 dpi with RB1B, and the size of the thymus
gradually returned to normal at 42 dpi (Figure 1A).
Compared with the control group, the thymus and body
weight parameters of the MDV-infected chickens dis-
played significant differences at 7, 21, 28 and 35 dpi
(Figure 1B).Differential expression in the MDV-infected chicken
thymuses at different time points
To obtain protein expression profiles at different time
points in the thymus from the MDV-infected and unin-
fected control chickens, total protein was collected from
the thymus specimens, separated by two-dimensional
electrophoresis and analysed using PDQuest 8.0.1 soft-
ware. More than 1000 protein spots could be detected in
each gel (Figure 2). In total, 250 protein spots were
detected as either quantitatively (p≤0.05 and fold
change≥2) or qualitatively differentially expressed (35
that were novel and 20 that were no longer visible) in
the thymus.These spots were predominantly identified atFigure 3 Comparison of the total numbers of protein spots that were
at the different time points. A total of 250 protein spots were detected,
28, 35 and 42 dpi, respectively. Notably, some of the protein spots were de
only 119 protein identities required MS analyses.21, 28 and 35 dpi, which was consistent with the patho-
logical observations (Figure 3).
MS analysis and GO annotations
Some protein spots were detected more than once dif-
ferentially expressed during experiment, resulting less
number of identities than the total number of spots. In
total, 119 differentially expressed proteins were success-
fully identified by MALDI-TOF/TOF (Table 1). These
proteins are involved in a wide range of biological pro-
cesses, including metabolism, immunity, apoptosis,
death, tumour development, virus infection and replica-
tion. More than 20 of the differentially expressed pro-
teins were directly associated with immunity, apoptosis,
tumour development and viral infection and replication,
including macrophage migration inhibitory factor (MIF),
heat shock protein 90 alpha (Hsp90alpha), and annexin-
A1 (Anx-A1).
Based on the GO annotations, more than 50% of the
associated biological processes were metabolic processes
(GO:0008152, 23.4%), regulations of biological processes
(GO:0050789, 17.3%) and responses to stimuli
(GO:0050896, 12.7%). In addition, the majority of the
associations, with respect to molecular function, were
with GO terms such as protein binding (GO:0005515,significantly differentially expressed in the MDV-infected thymus
among which 9, 33, 19, 77, 55, 43 and 14 were detected at 4, 7, 14, 21,
tected at least once during the different sampling points, and thus,
Table 1 Fundamental information of 119 differentially expressed protein spots identified by MS
SSP Protein Name Fold change in expression Accession
number
MW PI
4dpi 7dpi 14dpi 21dpi 28dpi 35dpi 2dpi
Actin cytoskeleton and cellular structural proteins
3908 collagen alpha-1(VI) chain precursor −1.05 1.57 1.44 4.53** 3.47** 1.14 1.65 gi|49225581 107916.8 5.63
3910 collagen alpha-1(VI) chain precursor 1.32 2.92** −1.66 3.77** 3.72* −1.73 .06 gi|49225581 107916.8 5.63
3914 collagen alpha-2(VI) chain precursor 1.01 1.79 1.54 4.11** −1.2 1.35 1.01 gi|45384382 109108.4 5.66
3915 collagen alpha-2(VI) chain precursor −1.33 2.24** 1.4 3.58** 1.71 1.89 .09 gi|45384382 109108.4 5.66
508 keratin, type I cytoskeletal 15 −1.22 −1.17 1.06 2.67** 1.28 −1.02 1.03 gi|47604932 48060.8 5.11
6713 keratin, type II cytoskeletal 1 −1.03 −1.68 1.23 −2.25** −1.43 −1.2 1.69 gi|119395750 65999 8.15
4502 keratin, type II cytoskeletal cochleal 1.69 −1.15 −2.55** −1.2 1.64 1.42 1.23 gi|45384378 53770.5 5.97
106 Chain B, Refined 1.8 Angstroms
Resolution Crystal Structure Of Porcine
Epsilon-Trypsin
1.34 −1.31 −1.14 −2.62** −2.28** −2.63** 1.29 gi|999627 8813.5 6.67
9222 PREDICTED: LOW QUALITY PROTEIN:
keratin, type II cytoskeletal 1-like
AB IN AB AB AB AB B gi|296211766 66379 8.16
6206 REDICTED: similar to Chain D, Crystal
Structure Of Arp23 COMPLEX
1.08 1.34 1.07 −1.04 −1.08 1.21 .14** gi|118093746 34379.6 6.84
6211 PREDICTED: similar to Chain D, Crystal
Structure Of Arp23 COMPLEX
−2.11** 3.72** 1.09 4.76** 2.22** 4.28** .73 gi|118093746 34379.6 6.84
314 beta-tropomyosin −1.19 1.04 1.37 1.82 1.66 2.86** .43 gi|212809 32779.7 4.77
6601 fibrinogen beta chain precursor −1.37 1.28 −1.01 1.88 2.33** −1.2 1.44 gi|267844833 54545.7 7.84
2606 plastin-2 −1.65 2.04** 1.23 2.44** 2.24* 2.13** .27 gi|56605886 69704.5 5.16
2206 beta-actin −1.1 1.87 1.08 1.06 1.53 2.08** .2** gi|154818367 41812.8 5.32
3906 collagen alpha-1(VI) chain precursor −1.07 1.67 1.51 4.29** 1.68 1.55 1.61 gi|49225581 107916.8 5.63
Enzymes
4406 adenylosuccinate synthetase isozyme 2 −1.29 1.1 −1.39 2.19* 2.2* −1.46 1.16 gi|71895783 49423.4 5.93
4410 argininosuccinate synthase 1.48 1.56 1.49 IN 3.99 2.64** 1.2 gi|61657937 46873.8 6.1
5402 argininosuccinate synthase −1.63 4.04** 1.03 1.15 1 1 1.45 gi|61657937 46873.8 6.1
5904 argininosuccinate synthase 1.35 2.49** 1.22 1.82 1.83 −1.23 1.67 gi|61657937 46873.8 6.1
6705 ATP-dependent RNA helicase DDX3X −1.03 −1.33 1.15 −2.2** −2.27** 1 1.55 gi|71895253 72004.5 6.54
3414 B-creatine kinase −1.32 1.73 −1.3 2.09** 1.76 1.34 1.08 gi|211235 42240.4 5.78
7213 L-lactate dehydrogenase A chain −1.08 1.71 −1.03 2.36** 2.63** 2.43** 1.4 gi|45384208 36491.2 7.75
6606 phosphoglucomutase 2 AB REP REP −1.36 AB −1.4 .29 gi|71897287 67900.1 6.56
9221 PREDICTED: similar to 2,4-dienoyl-CoA
reductase
AB IN AB AB AB AB B gi|50731694 35723.5 9.46









































Table 1 Fundamental information of 119 differentially expressed protein spots identified by MS (Continued)
3207 RecName: Full=3-mercaptopyruvate
sulfurtransferase; Short=MST
AB AB IN AB AB AB B gi|90110410 33002.5 6.11
6107 RecName: Full=Carbonic anhydrase 2; AltName: −1.13 −1.45 1.13 1.38 3.04 1.19 .22* gi|115454 29388.4 6.56
Full=Carbonate dehydratase II; AltName:
Full=Carboni anhydrase II; Short=CA-II
2622 PREDICTED: similar to serine/threonine
kinase isoform 1
AB 1.17 1.44 REP −1.22 −1.43 2.46** gi|118094908 57883.8 6.04
4117 PREDICTED: similar to Glyoxylase 1 REP AB AB AB AB AB B gi|50740506 20540.2 6.1
6402 creatine kinase M-type AB 1.16 1.32 2.64* 2.68** 2.47** 1.04 gi|45382875 43301 6.5
6408 creatine kinase M-type −1.39 2.07* 1.75 6.7** 1.14 2.27 1.06 gi|45382875 43301 6.5
6414 enolase 1.24 1.18 1.28 1.59 2.38** 1.4 .25 gi|116248308 41047.2 5.62
9101 glutathione S-transferase 1.04 1.99 1.39 2.47** 2.7** 2.58** 1.13 gi|49169816 25282.4 8.86
4210 PREDICTED: gemin 4 −1.58 1.18 1.56 −1.24 1.07 −2.17** 1.37 gi|224076562 30154.9 4.96
1109 cathepsin B precursor 1.02 −1.03 1.04 2.27** 2.39** 2.86** .04 gi|46195455 37562.7 5.74
5607 peptidase D −1.39 1.49 IN 1.73 IN 2.08** 1.21 gi|169139269 55101.6 6.07
9111 peptidyl-prolyl cis-trans
isomerase B precursor
1.15 1.55 1.12 2** 1.78 1.88 1.17 gi|45382027 22398.8 9.4
6111 PREDICTED: similar to
Glutathione S-transferase
theta 1 isoform 3
1.55 −1.1 −1.59 −2.38** −1.56 −3.36** .13 gi|118098704 27843.7 6.25
Immunity, apoptosis, tumor development
and viral infection and replication
6507 septin-6 −1.15 −1.27 −6.03** −1.82 −1.35 −1.39 .2 gi|71895629 48656.9 6.67
6521 septin-6 1.1 1.25 2.42** −1.3 −1.05 −1.15 1.55 gi|71895629 43021.1 6.63
7310 septin-9 −1.08 −1.38 −1.08 −2.87** −2.09* −2.33* 1.25 gi|71897123 65482.8 8.42
3203 PREDICTED: similar to
PTB-associated splicing factor
AB AB −2.1** AB −2.75** −1.09 .06** gi|118101662 69173.9 9.43
7116 PREDICTED: heterogeneous
nuclear ribonucleoprotein A3
−1.97 2.16** −1.67 11.96** 2.33** 2.4** .4 gi|118093536 40603.2 9.24
8310 PREDICTED: heterogeneous
nuclear ribonucleoprotein A3
AB AB AB −6.86** AB AB B gi|118093536 40603.2 9.24
1310 PREDICTED: heterogeneous
nuclearribonucleoproteins C1/C2-like
−1.22 −1.19 −1.04 −3.14** −2.43* −1.36 .29 gi|296224780 23551.2 9.87
8304 heterogeneous nuclear ribonucleoprotein A/B 1.02 1.29 −1.92 −2.39** −2.58** −2.11** 1.18 gi|45384514 31841.8 8.62
2613 heterogeneous nuclear ribonucleoprotein H −1.14 −1.78 1.87 −2.13** −3.36 −2.48 .05 gi|45383173 56530.6 5.38
2610 heterogeneous nuclear ribonucleoprotein H 1.22 −2.25* −1.31 AB −2.11** −1.82 2.91 gi|45383173 56530.6 5.38






































Table 1 Fundamental information of 119 differentially expressed protein spots identified by MS (Continued)
8211 heterogeneous nuclear ribonucleoproteins A2/B1 −1.1 −1.11 1.06 −2** −2** −1.68 1.12 gi|71896753 36962.4 8.67
8213 heterogeneous nuclear ribonucleoproteins A2/B1 1.04 −1.07 −1.46 −2.53** −1.41 −2.01** 1.1 gi|71896753 36962.4 8.67
9205 heterogeneous nuclear ribonucleoproteins A2/B1 −1.08 1.07 −1.41 −2.47** −2.19** −1.57 1.12 gi|71896753 36962.4 8.67
7006 macrophage migration inhibitory factor 1.35 −1.03 −2.04** −1.64 −1.77 −1.84 .74 gi|212258 12704.2 6.88
2905 heat shock protein HSP 90-alpha −1.37 −1.55 −1.23 −3.73** −1.58 −1.63 1.67 gi|157954047 84006.5 5.01
7215 annexin A1 AB IN 1 IN IN IN B gi|46195459 38475.9 7.05
7703 far upstream element-binding protein 1 1.03 −2.56 1.34 −2.53** −2.38* −1.85 1.48 gi|83320094 67155.3 7.18
3014 stathmin 1.19 1 −1.16 −4.27** −7.72** −7.18** .05 gi|50053682 17071.9 6.18
4003 stathmin 1.1 −2.1** −1.1 −4.91** −4.49** −5.08** 1.1 gi|50053682 17071.9 6.18
405 vimentin −1.5 3.27* 1.56 3.31** 1.36 1.06 .04 gi|114326309 53109.6 5.09
1605 vimentin 1.62 1.76 1.77 2.9** −1.35 −1.08 1.01 gi|114326309 53109.6 5.09
409 vimentin 1.23 1.64 1.42 2.26** 1.47 1.31 gi|114326309 53109.6 5.09
205 nucleolar protein B23/No38 1.28 1.76 −1.51 1.54 1.58 1.65 .95** gi|212456 10716.2 4.38
6003 beta-galactoside-binding lectin 1.07 2.22** 1.56 2.7** 2.66** 2.4** 1.45 gi|45382785 15053.5 6.58
3113 PREDICTED: similar to natural killer
cell enhancing factor isoform 4
1.63 1.12 1.63* 1.58 2.5** 2.28** 1.27 gi|50751518 22300.5 8.24
5304 unnamed protein product 1.23 1.88 1.45 −1.49 −1.26 1.28 .11** gi|74142813 50433.1 6.17
1104 PREDICTED: similar to interferon,
gamma-inducible protein 30
1.14 −1.05 −1.04 −2.27** −1.29 −1.12 .19 gi|50761132 14269.9 5.73
401 mCG49244 1.23 −1.56 1.27 −2.25* −2.04** −1.63 1.73 gi|148694498 21747.1 5.71
114 SET 1.62 5.16** 1.18 −1.01 −1.07 1.01 .51 gi|3953617 24348 4.97
Mitosis, replication and translation
1402 put. beta-actin (aa 27–375) 1.01 −1.27 −2.74** −13.22** −14.21** −1.1 1.07 gi|49868 39160.6 5.78
2303 suppressor of G2 allele of SKP1 homolog AB −2.33* −1.1 REP REP REP EP gi|71895155 20497.5 6.35
6307 mitotic checkpoint protein BUB3 AB −3.53** 1.61 REP REP REP 2.97** gi|57529813 37256.3 6.5
3501 PREDICTED: similar to eukaryotic
translation initiation factor 4H isoform 1
1.26 −2.31* −1.33 −1.99 −1.45 −1.84 .02 gi|126314438 27406.4 6.78
8202 PREDICTED: similar to eukaryotic
translation initiation factor 4H isoform 1
1.17 −3.81** 1.13 −2.86** −1.72 −1.38 2.65** gi|126314438 27406.4 6.78
2013 PREDICTED: similar to histone H2B 3.97* REP REP REP REP REP .73** gi|149617840 29704.7 9.68
7117 single-strand binding protein AB AB AB IN IN IN B gi|42523087 15766.8 6.13
5603 pre-mRNA-processing factor 19 1.61 −1.34 −2.62** −1.23 −1.09 −1.32 1.16 gi|86129600 55100.2 6.19
Signal transduction
3616 Amb7 1.22 1.9 1.94 4.4** 1.87 IN B gi|117168610 225516.8 5.61











































Table 1 Fundamental information of 119 differentially expressed protein spots identified by MS (Continued)
6102 coronin-1C −1.1 1.32 −1.33 2.41** 3.78* 3.37** .76** gi|86129440 53174.1 6.22
3015 fatty acid-binding protein, adipocyte −2.05** 2.38* 2.34** 4.91** 4.73** 2.39** .11 gi|45383556 14884.6 6.34
3012 fatty acid-binding protein, heart −1.23 −1.49 AB 9.97** 1.5 1.62 .77 gi|71894843 14806.6 5.92
3709 Lipocalin precursor 1.75 −1.47 1.09 4.11** 6.62** 3.26* .47 gi|225716896 20257.1 7.6
6213 PREDICTED: similar to GADS protein −1.46 −1.24 1.56 −2.49** 1.7 −1.08 .19 gi|118082689 33178.5 6.23
5205 PREDICTED: similar to GADS protein −1.11 −2.14** −1.15 −3.84** 1.04 −1.16 1.45 gi|118082689 33178.5 6.23
6310 PREDICTED: similar to nucleic acid
binding protein isoform 2
1.42 −1.6 −1.03 −1.41 −2.07** −1.59 1.63 gi|126345445 35784.3 7
6011 PREDICTED: similar to retinoid binding protein 7 −4.75** IN IN IN IN 4.34** B gi|118101075 14701.2 5.31
1008 thioredoxin −1.26 −1.11 −1.02 2.46* 1.28 1.7 .07 gi|45382053 11692.8 5.1
Transport
6517 ferritin heavy chain −1.14 2.81** −1.44 2.13** 4.11** 2.25** .02 gi|45384172 21078.3 5.78
7203 ferritin heavy chain −4.57** 1.42 −1.18 3.89** 2.12** 2.49** .03 gi|45384172 21078.3 5.78
8018 hemoglobin alpha-A chain −3.13** 1.13 1.41 1.37 1.2 1.4 .26 gi|4894665 10914.7 7.19
8003 hemoglobin alpha-A chain −2.54** −1.15 −1.12 −1.03 1.28 −1.14 .06 gi|4894665 10914.7 7.19
6009 hemoglobin subunit alpha-D −1.08 −1.07 3.59** 1.2 1.02 1.04 .03 gi|52138645 15685 7.01
6804 ovotransferrin BB type 1.03 1.32 −1.27 2.71* 1.82 1.78 .03 gi|71274075 77781.4 6.85
6810 ovotransferrin BB type AB 1.95 REP 20.2* IN IN B gi|71274075 77781.4 6.85
6801 ovotransferrin CC type 1.56 1.27 1.19 2.52** 2.89* 2.48* 1.17 gi|71274077 77750.4 7.08
7201 mediator of cell motility 1 1.37 −1.06 1.02 −2.93** −1.09 1.54 1.24 gi|300676818 31517.5 6.49
Others proteins
6104 603815993F1 CSEQCHN52 Gallus gallus
cDNA clone ChEST809j23 50, mRNA sequence
1.14 −1.17 −1.57 −2.53** −2.12** −1.94 .19 gi|25541234 23338.9 6.03
304 alpha-tropomyosin (partial) −1.32 1.18 1.12 2.37** 2.38** 2.46** .71 gi|212815 30045.3 4.64
5815 conalbumin −1.17 1.11 −1.05 5.97* 3.44** 1.9 1.12 gi|295721 79551.1 6.85
4012 cytoChrome c subfamily, putative AB IN AB IN IN 26.4 B gi|124005227 24128.2 9.21
307 putative nucleophosmin 1 variant 1 1.2 −2.66* 1.23 −2.09** −3.13** −1.19 .06 gi|45383996 32612 4.66
4412 putative protein product of Nbla10058 AB IN AB AB AB AB B gi|76879893 48587.2 5.85
204 PREDICTED: similar to Acidic leucine-rich nuclear 1.3 −1.71 −1.6 −2.22* −3.2** −2.45** 1.14 gi|118096008 32075.9 3.98
4420 PREDICTED: similar to cyclophilin AB AB AB IN IN AB B gi|118089782 39402.9 5.61
6304 PREDICTED: similar to KIAA0089 1.01 −1.19 −1.45 −1.43 −2.6** −1.8 .2 gi|50732786 38564.1 6.55
4116 PREDICTED: similar to LOC129607 protein −1.25 IN AB IN IN IN B gi|118088982 31865.5 8.45
4114 PREDICTED: similar to MGC84496 protein −1.43 −1.32 −1.37 1.17 1.64 1.98 .77** gi|118101652 22693.7 6.07












































Table 1 Fundamental information of 119 differentially expressed protein spots identified by MS (Continued)
1006 transthyretin precursor −1.12 −1.01 1.35 −2.64** −3.31** −1.57 −1.09 gi|45384444 16299.1 5.11
Hypothetical proteins
3507 PREDICTED: hypothetical protein 1.52 −1.52 −1.24 −3.08** −2.04* −1.49 −1.31 gi|50762370 47124.5 5.64
2203 PREDICTED: hypothetical protein −1.37 −1.72 −1.72 −6.61** −2.27** −3.83** −1.02 gi|118087111 30122.5 5.51
2209 PREDICTED: hypothetical protein −1.12 −1.22 −2.19** −1.3 −1.27 1.14 1.43 gi|118092623 32616.1 5.53
3110 PREDICTED: hypothetical protein AB −2.73** IN AB −3.04** −2* −1.22 gi|118084734 18881.6 6.08
5108 PREDICTED: hypothetical protein −5.55** REP REP −1.2 IN REP 1.75 gi|118084734 18881.6 6.08
7214 PREDICTED: hypothetical protein −1.48 1.03 −2.13** −1.46 1.88 1.06 −1.04 gi|50762370 47124.5 5.64
2307 hypothetical protein −1.24 1.82 1.47 1.39 1.55 2.28* 2.19** gi|53126859 42107.9 5.31
4013 hypothetical protein Bsuib36_09931 AB AB AB IN AB AB AB gi|254704229 122393.8 8.07
3210 hypothetical protein PANDA_003704 AB AB AB IN AB AB AB gi|281343027 31307.8 5.44
Fold change = infected/control. Positive indicates up regulation, negative indicates down-regulation.
IN = induced, detected only in infected group, REP = repressed, detected only in the control group, AB = absent in both groups, dpi = days post-infection.
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http://www.virologyj.com/content/9/1/25627.2%), nucleic acid binding (GO:0003676, 13.6%) and
hydrolase activity (GO:0016787, 12.3%). Meanwhile,
7.0% of the proteins were associated with functions such
as signal transduction, antioxidation, transcription regu-
lation and receptor binding.Analysis of the protein functional interaction networks
The STRING Database was used to establish possible
interactions among the detected proteins. In this ana-
lysis, 16 tumour proteins were identified by interaction
analysis, and a network map with the tumour protein
p53 (TP53), myc proto-oncogene protein (MYC) andFigure 4 Based on the STRING database, the network of protein–prot
differentially expressed proteins formed a network map with the tumour p
inducible factor 1-alpha (HIF1A) at its core.hypoxia-inducible factor 1-alpha (HIF1A) at its core was
obtained (Figure 4).
Validation of the mRNA expression levels using real-time
PCR
To validate the results of the proteomic analysis, the ex-
pression levels of ANXA1, MIF, NPM1, OP18 and VIM in
the chicken thymus were determined using real-time PCR.
The mRNA expression levels of these proteins were down-
regulated at 4 dpi and then remained down-regulated for
MIF and OP18 and up-regulated for ANXA1 and VIM
(Figure 5). These results are consistent with the results of
our proteomic analysis (see Table 1 and Figure 5).ein interactions in the MDV-infected thymuses. Sixteen
rotein p53 (TP53), myc proto-oncogene protein (MYC) and hypoxia-
Figure 5 mRNA changes for the five proteins that were significantly altered in response to the MDV infection at the different stages.
The y-axis is the fold change, with the positive values representing up-regulation and the negative values representing down-regulation. The
abscissa axes represent different stages.
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chickens
The MDV infection levels in the thymus at seven points
were detected using real-time PCR and are shown in
Figure 6. The expression level of gB was transiently
increased at 4 and 7 dpi and decreased at 14 dpi, the latent
infection phase. The gB expression level was increased
again at 21 dpi, suggesting the occurrence of MDV reacti-
vation and transformation, and decreased at 28 dpi. These
changes were consistent with the numbers of differentially
expressed proteins. After 28 dpi, the mRNA level of gB inFigure 6 mRNA levels of the MDV transcripts in the chicken thymuse
were detected using real-time PCR and calculated using the 2 –ΔΔCT meththe MDV-infected chickens displayed a rapid decrease,
and little mRNA was detected at 42 dpi. These changes
coincided with the Meq expression levels.
Discussion
The thymus is the specific organ in which the maturation
and differentiation of avian T-lymphocytes take place. T
lymphocytes, or T cells, are of a key importance to the im-
mune system and are at the core of adaptive immunity.
Chickens infected with MDV display thymic atrophy
(Figure 1A) and eventually the formation of T-cells infected with RB1B. The expression levels of Meq and gB mRNA
od.
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mechanisms of this phenomenon. In the present study,
119 proteins differentially expressed in thymus specimens
from chickens infected with MDV were identified by two-
dimensional electrophoresis and mass spectrometry at
seven time points. The chicken thymuses displayed severe
atrophy at 21, 28 and 35 days after infection with RB1B,
and their size gradually returned to normal at 42 dpi. The
change in thymus size during the course of the MDV in-
fection may have influenced the expression of cellular
structural proteins, enzymes and cytoskeleton proteins.
However, we should also note that the 2-DE and real-time
PCR analyses were conducted using the same amounts of
protein and mRNA, which might exclude the effect of thy-
mus size to some extent. In addition, the change in the
cellular composition of the thymus could be affected the
total proteome. The thymic atrophy in the chickens
infected with MDV has a significant influence on host im-
mune suppression. Permanent immunosuppression tends
to correlate with the eventual development of tumours,
which enhances our understanding of the mechanisms of
T-lymphoma formation.
To better understand host responses to MDV infec-
tion, the expression of viral genes (gB and Meq) was
detected using real-time PCR (Figure 6). We found a
good correlation between viral gene product and host
differentially expressed proteins. The expression levels of
gB and Meq were transiently increased at 4 and 7 dpi
and decreased at 14 dpi during the latent infection
period. The gB and Meq expression levels were again
increased at 21 dpi, suggesting the occurrence of MDV
reactivation and transformation (Figure 6). At 21 dpi,
the over-expressed viral gene products led to serious
changes in protein expression levels and thymic atrophy
(Figures 1, 3 and 6). These changes could be due to the
disease pathology induced by MDV infection. Consistent
with the MDV pathogenesis, early cytolytic infection oc-
curred at 3 to 7 dpi and then entered latency, followed
by the proliferative/transformation phase, leading to
lymphoma formation at approximately 21 to 28 dpi.
After 28 dpi, the mRNA levels of gB and Meq in the
MDV-infected chickens displayed a rapid decrease, and
little mRNA was detected at 42 dpi. This change may be
due to the cellular response of lesion regression. It has
been reported that lymphomas can occur at any time
from approximately 3~4 weeks, and lesion regression
can occur after lymphomas [13].
More interestingly, more than 20 differentially expressed
proteins were directly associated with immunity, apoptosis,
tumour development and viral infection and replication
(Table 1). Notably, at least nine proteins were identified for
the first time in this study: macrophage migration inhibitory
factor, heat shock protein 90-alpha, annexin A1, far up-
stream element-binding protein 1, septin-6, septin-9, beta-galactoside-binding lectin, mCG49244 and an unnamed
protein product. Among these proteins, some formed a net-
work map encompassing TP53, MYC and HIF1A at its core
and are directly associated with immunity, apoptosis,
tumour development and viral infection and replication
(Figure 4). Within this map, we found that MIF,
HSP90AA1, NPM1, STMN1(OP18) and VIM can interact
with the tumour suppressor protein TP53. It has been
reported that the Meq oncoprotein directly interacts with
p53 and inhibits p53-mediated transcriptional activity and
apoptosis [14]. This scenario could provide an interesting
link between MEQ and these proteins and enhance our
understanding of MDV pathogenesis. The mRNA levels of
these proteins were confirmed by real-time PCR (Figure 5),
and some of these proteins are further discussed in this
study.
Roles of the differentially expressed proteins in MDV
infection
After MDV infection, the expression of the MIF protein
displayed a slight increase at 4 dpi, followed by a down-
regulation and subsequent increase at 42 dpi. The mRNA
expression level of MIF was down-regulated at all stages,
which may have resulted for two reasons. First, different
mechanisms control the transcription and translation of
the MIF gene in chicken thymus, and the mRNA abun-
dance is not always consistent with the protein level. Sec-
ond, it is possible that the transcription level of the MIF
gene is easily influenced by MDV during the early stages
of the infection. However, MIF is a pro-inflammatory fac-
tor, and its translational level is enhanced by the host’s
regulatory mechanisms. Notably, the differences in the ex-
pression levels of the MIF mRNA and protein could be
involved in the MDV infection. It is believed that macro-
phages transfer the virus to B cells, which are the primary
target cells that are infected between 3 and 6 days post-
infection [4]. A heavy infiltration of lymphocytes and
macrophages occurs around blood vessels at 8–10 days
post-MDV infection [15], and a study has demonstrated
that some new MDV strains can replicate in macrophages,
which leads to increased macrophage death [16]. MIF is
involved in virus infection, and its target cells are mainly
macrophages. It has been reported that human cyto-
megalovirus (HCMV), a herpesvirus, paralyses macro-
phage motility through the down-regulation of chemokine
receptors, reorganisation of the cytoskeleton, and release
of MIF [17]. MIF also promotes HIV-1 replication through
the activation of HIV-1 long terminal repeats (LTR) [18].
Increased MIF at 4 dpi may promote MDV replication.
The down-regulation of MIF indicates a strong macro-
phage migration activity, and macrophages that carry
MDV could spread the MDV infection to other cells. An-
other protein, Anx-A1, was induced at 7, 21, 28 and 35
dpi and may be associated with MDV infection. Research
Table 2 Primers used for real-time PCR
Gene Symbol Nucleotide sequence Product size (bp) Accession number
MIF F 50-GCCCGCGCAGTACATAGC-30 57 XM42_5824
R 50-CCCCCGAAGGACATCATCT-30
OP18 F 50-TTGAGCTGATCCTTGGTCCC-30 128 NM_001001858.1
R 50-CTTGCGTCTCTCTTCTGC-30
VIM F 50-CAACACGGAGTTCAAGGCGA-30 79 NM_001048076.1
R 50-GATGTAGTTGGCGAAGCGGT-30
NPM1 F 50-GGTTACATTAGGGGCTGG-30 73 NM_205267.1
R 50-GTTGCCTTCGTAGTCCAGTG-30
ANXA1 F 50-AAAACTGCCTGACTGCCCTT-30 90 NM_206906.1
R 50-TTCCACTCCCCTTCATTGCC-30
Meq F 50-GTCCCCCCTCGATCTTTCTC −30 184 NC_002229.3
R 50-CGTCTGCTTCCTGCGTCTTC-30
gB F 50-ACCCCATTCGGTGGCTTTTC-30 122 NC_002229.3
R 50-GCGTCCAGTTGTCTGAGG-30
GAPDH F 50-AGGGTGGTGCTAAGCGTGTTA-30 78 NM_204305
R 50-TCTCATGGTTGACACCCATCA-30
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involved in the viral replication cycle, which may integrate
the regulation of virus infection by forming networks [19].
Nucleolar protein B23 (NPM1), an acidic nucleolar pro-
tein, was up-regulated in the thymus of chickens infected
with MDV and may indicate the nuclear importation of
MDV. It has been demonstrated that NPM1 stimulates
the nuclear importation of the HIV-1 Rev protein [20],
and NPM1 is also an important factor for the nucleolar lo-
calisation of the HIV protein Tat [21]. The reduction in
the Hsp90alpha level during early MDV infection might
be related to a latent infection. Hsp90 plays an important
role in the replication and infectivity of some herpes-
viruses, such as herpes simplex virus type 1 [22], Epstein–
Barr virus (EBV) [23] and Kaposi’s sarcoma-associated
herpesvirus (KSHV) [24], and is required for the folding,
stability and intracellular transport of multiple viral pro-
teins and for the activity of viral polymerases. Taken to-
gether, our observations suggest that changes in the levels
of these proteins influence MDV replication and infection.
However, the specific mechanisms are unknown and will
require further study.The chicken immune response to MDV infection
Suppression of the immune response by MDV infection
is a critical feature of the disease. MIF down-regulation
may contribute to the inhibition of the immune re-
sponse. MIF, a classic pro-inflammatory cytokine and a
pivotal regulator of innate immunity, promotes innate
and adaptive immune responses through the activation
of macrophages and T cells [25,26]. Moreover, it directlyinhibits the immunosuppressive actions of glucocorti-
coids [27] through the suppression of mitogen-activated
protein kinase (MAPK) phosphatase-1 (MKP-1) [28-30].
MKP-1, which is induced by glucocorticoids, inactivates
the proinflammatory ERK1/2, JNK, and p38 pathways.
Anx-A1, a pivotal regulator of the innate and adaptive
immune systems, also promotes immunosuppression
[31]. This protein was induced at 7, 21, 28 and 35 dpi
and has a powerful suppressive effect on the innate im-
mune system. Recent investigations on the role of this
protein in the adaptive immune response have revealed
a previously unknown ‘dark side’ to this protein, that is,
it is a positive modulator of T cell activation [32]. High
levels of Anx-A1 influence the differentiation of T cells
in vivo, and hence, may contribute to the development
of T-cell-driven autoimmune diseases.
While heat shock proteins are molecular chaperones,
they have also been implicated in the stimulation of the
innate and adaptive immune systems [33,34]. Recent
biochemical evidence highlights the role of Hsp90alpha
in the endogenous processing of MHC class I antigens,
and the absence of Hsp90alpha results in the decreased
surface expression of MHC I [35]. Levy et al. [36]
reported that RB1B was able to markedly decrease MHC
class I expression. In addition, those authors found that
MDV pUL49.5 directly down-regulates MHC class I ex-
pression [37], and beta2 microglobulin was also
decreased in the bursa of Fabricius of chickens infected
with RB1B [6]. A subsequent gene expression study indi-
cated a down-regulation of MHC class II expression in
the spleens of MDV-infected chickens [9]. The specific
relationship between the down-regulation of HSP90A
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infection is not yet clear. However, these findings indi-
cate that a potential mechanism of immune evasion
mediated by MHC expression on cell surfaces might be
employed by MDV. In addition, the immune suppression
that occurs after MDV infection is not only related to
changes in immune-related proteins but may also be
associated with immune evasion.
Apoptosis and thymic atrophy after MDV infection
The thymic atrophy of chickens infected with MDV is
the most significant manifestation of immune suppres-
sion and might be related to apoptosis. Morimura et al.
reported that MDV can induce apoptosis and the down-
regulation of CD8 molecules on peripheral CD4+ T cells
and in the thymus, which could contribute to immune
suppression [10-12]. In this study, although we did not
detect cell apoptosis by flow cytometry, changes in some
proteins indicated apoptosis in the thymuses of the
chickens. According to the network of protein–protein
interactions in the thymuses infected with MDV, five dif-
ferentially expressed proteins can interact with P53
(Figure 6). The decreased levels of stathmin/oncopro-
tein18 (Op18) and MIF may increase the level of p53
and promote p53-mediated apoptosis before T-cell
lymphoma formation. It has been demonstrated that
MIF suppresses the expression of p53 and its activity
[26,38]. MIF increases resistance to apoptosis by activat-
ing the nuclear factor-kappa B (NF-κB) system and
repressing the function of p53 [39]. Changes in Op18
may be related to the increase in P53 because p53 is
associated with the negative regulation of stathmin ex-
pression [40-42]. In the thymus, this protein was mainly
down-regulated and was significantly differentially
expressed at 21, 28 and 35 dpi. Lu et al. [6] also reported
that Op18 was significantly reduced at 4, 7 and 21 dpi in
the bursa of Fabricius of chickens infected with RB1B. In
addition, ANX-A1 is relevant to the regulation of cell
growth and apoptosis [43,44], and ANXA1 overexpres-
sion has been shown to promote apoptosis [45,46]. It
has also been reported that ANXA1 expression in leu-
kaemic cells mediates the engulfment of apoptotic cells
by macrophages [47]. In short, MDV infection results in
immune suppression and the induction of apoptosis,
which eventually leads to thymic atrophy.
T-cell lymphoma formation during MDV infection
The Meq oncoprotein of the Marek’s disease virus is the
major oncogene involved in the induction of tumours and
inhibits p53 transcriptional and apoptotic activities by
interacting with p53 [14]. Permanent immunosuppression
tends to correlate with the eventual development of
tumours. The role of host proteins associated with tumour
growth and metastasis in the formation of T-celllymphoma cannot be ignored. MIF, a negative regulator of
the important tumour suppressor p53, is involved in
tumour occurrence and evolution [48-50]. A significant
amount of evidence indicates that MIF influences several
important biological mechanisms and processes by which
tumours thrive and spread. One of the most important of
these mechanisms is the modulation of hypoxic adapta-
tion within the tumour microenvironment through the
direct promotion of the hypoxia-induced stabilisation of
HIF-1α [51]. We speculate that the increased level of MIF
protein observed at 42 dpi may indicate hypoxic adapta-
tion within the tumour microenvironment. Anx-A1 is dir-
ectly related to tumour development [52]. This protein
was induced at 7, 21, 28 and 35 dpi and could be a key
host factor that enhances the formation of T-cell lymph-
omas. Strong evidence for this process is provided by the
finding that the increased expression of Anx-A1 promotes
tumour growth, invasion and metastasis in gastric carcin-
oma [53], melanoma [54], breast cancer [55] and colorec-
tal cancer [56]. Using AnxA1- knock out (KO) mice, it has
been determined that tumour growth and metastasis are
significantly decreased, whereas rodent survival and
tumour necrosis are significantly increased when tumours
grow in AnxA1-KO mice [57]. In addition, the up-
regulation of several cytoskeletal network proteins, e.g.,
vimentin, beta-actin and keratin (type I cytoskeletal 15),
also promotes tumour growth and metastasis. Research
suggests that vimentin, a major intermediate filament (IF)
protein of mesenchymal cells, is very important for
tumour growth and metastasis [58,59]. Beta-actin specific-
ally controls cell growth and migration [60], and an in-
crease in beta-actin levels correlates with a higher level of
invasiveness for a select hepatoma in Morris 5123 cells
[61]. Changes in these proteins indicate that MDV infec-
tion and T-cell lymphoma formation involve the host
cytoskeleton. Nucleolar protein B23 (NPM1) plays mul-
tiple roles in cell growth and proliferation [62].
Thanthrige-Don et al. also reported an up-regulation of
beta-actin and NPM1 in the spleens of MDV-infected
chickens [5]. Interestingly, a report has shown that the
interaction between Meq and Hsp70 is significant during
MDV oncogenesis [63]. However, the biological conse-
quences of the Meq–Hsp70 interaction are not clear. Fi-
nally, HSP90A was reduced at 21 dpi; however, whether
HSP90 can interact with Meq and affect Meq carcinogen-
icity remains to be studied.
In addition, septin 9 and septin 6 levels were significantly
decreased in the thymuses of chickens infected with MDV.
Septins are a highly conserved family of GTP-binding cyto-
skeletal proteins implicated in oncogenesis [64,65]. Septin 9
(SEPT9), a DNA methylation-based biomarker, has been
functionally linked with oncogenesis through its activation
of the hypoxia-inducible factor-1 (HIF-1) pathway, which
promotes tumour progression, and the c-Jun-N-terminal
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proliferation, cell transformation, and tumour progression
[66,67]. The differential expression of heterogeneous nu-
clear ribonucleoproteins (hnRNPs), including HnRNP A /
B, HnRNP A2/B1, HnRNP H, and HnRNP C1/C2, was also
detected in this study. These proteins play key roles in
tumour development and progression [68]. Studies have
shown that hnRNP A2 / B1 and hnRNP A1 can combine
their telomere DNA sequences and that their encoded pro-
tein isoforms can interact with the telomerase. Tumour
cells fail to enter senescence due to their telomere lengths,
which are maintained by telomere-bound proteins that re-
cruit the enzyme telomerase [68,69]. Currently, the roles of
septins and hnRNPs in MD tumour progression are not
clear and require further study.Conclusions
This paper provides a proteomic profiling of host
responses to MDV in the thymus of chickens. Changes in
protein levels partially elicited the mechanisms involved in
MDV oncogenesis and pathogenesis. The functions of
these proteins will be verified in our future works.Methods
Experimental animals and virus
All chickens used in this study were 1-day-old specific-
pathogen-free white Leghorns obtained from Merial
Vital (Laboratory Animal Technology Co., Ltd., Beijing,
China). The chickens were housed in an isolation facility
at the College of Veterinary Medicine, Yangzhou Univer-
sity. The RB1B strain of very virulent MDV was main-
tained in the laboratory.Experimental design
The experimental work was performed as reported previ-
ously [6]. Briefly, a total of 48, 1-day-old birds were ran-
domly divided into infected and uninfected control groups
and kept in separate units under similar environmental
conditions. The infected group (n = 24) was given 800
plaque-forming units of the RB1B virus intraperitoneally
at 1 day old. At 4, 7, 14, 21, 28, 35 and 42 dpi, six chickens
(three infected and three uninfected control birds) were
sacrificed, and the whole thymus was excised rapidly,
rinsed with ice cold phosphate-buffered saline (PBS, pH
7.4) to remove blood contaminants and immediately
stored in liquid nitrogen until the proteomic and real-time
PCR analyses. The animal experiments were conducted in
accordance with the guidelines provided by the Chinese
Council on Animal Care. All experiments complied with
institutional animal care guidelines and were approved by
the University of Yangzhou Animal Care Committee
(protocol number 06R015).Sample preparation
The samples of thymus protein were prepared as previ-
ously described [6]. Frozen thymus tissue was ground
into a fine powder in liquid nitrogen with a pre-chilled
mortar and pestle. This ground tissue was used for both
the protein and real-time PCR analyses. Five milligrams
of ground tissue was dissolved directly in 1.0 ml of ex-
traction buffer (8 M urea, 2 M thiourea, 2% CHAPS,
60 mM DTT (dithiothreitol), 0.2% Bio-Lyte 3∕10 ampho-
lyte, 0.1% Bio-Lyte 5∕8 ampholyte and 0.001% bromophe-
nol blue) and shaken on ice for 2 h. A cocktail of protease
inhibitors (Sigma) was added every two hours during sam-
ple preparation to protect the proteins from degradation.
The homogenate was sonicated, gently shaken on ice for
4 h and subsequently centrifuged at 16,000 g (5415 R
Eppendorf) for 70 min (16°C). The supernatant was col-
lected and stored at −20°C. Protein concentrations were
determined using the Bradford method [70].
2-DE
Protein sample (300 μg) was incubated for 30 min at 20°C
in 400 μl rehydration buffer (8 M urea, 2 M thiourea, 2%
CHAPS, 60 mM DTT, 0.2% Bio-Lyte 5∕8 ampholyte, 0.2%
Bio-Lyte 3∕10 ampholyte and 0.001% bromophenol blue)
and centrifuged at 16,000 g (5804 R Eppendorf) for
10 min (16°C). The supernatant was collected, and Ready-
Strip IPG strips (17 cm, pH 3–10 nonlinear gradient, Bio-
Rad) were rehydrated overnight at 20°C in a PROTEAN
IEF focusing tray (Bio-Rad, USA). After rehydration, iso-
electric focusing (IEF) was performed at 20°C using a
Protean IEF Cell (Bio-Rad, USA) and the following condi-
tions: 250 V, slow, 0.5 h; 500 V, linear, 0.5 h; 1000 V, rapid,
1 h; 8000 V, linear, 4 h; 8,000 V, rapid, 55,000 V-hr; 500 V,
rapid, any time. After IEF, the IPG strips were incubated
in SDS-PAGE equilibration buffer I (6 M urea, 0.375 M
Tris–HCl, pH 8.8, 2% (w/v) SDS, 20% (v/v) glycerol and
2% (w/v) DTT) and buffer II (the DTT was replaced with
2.5% (w/v) iodoacetamide), with a 10-min incubation for
each buffer. The strips were then loaded onto 11% homo-
geneous acrylamide gels and sealed with 0.5% (w/v) aga
rose in SDS running buffer (25 mM Tris base, 192 mM
glycine, 0.1% (w/v) SDS). The second dimension, the
SDS-PAGE, was run at 20°C using a PROTEAN II Multi-
Cell (Bio-Rad, USA). The run was first conducted at 16
mA/gel for 30 min followed by 24 mA/gel for 5 h. The
gels were stained using the colloidal Coomassie stain
method [71] and Brilliant Blue G-250.
Image analysis
The stained gels were scanned at a 600 dpi (dots per
inch) resolution using a PowerLook 2100XL scanner
(Umax, USA). Automated detection and matching,
quantification and annotation of spots were performed
using the PDQuest software package (version 8.0.1, Bio-
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three uninfected control bird samples, and each sample
was repeated 2~3 times. Finally, we selected three repre-
sentative gels for the control group and three for the
infected group, the reproducibility within each group
was approximately 85% or better. The gel images were
then normalised according to the total quantity in the
analysis set. Protein spots (FC≥2) were compared using
Student’s t-test and the Statistical Package for the Social
Sciences (version 16.0). Spots that had both P≤0.05 and
≥2-fold difference in mean normalised volumes were
considered significantly different.
Protein identification
Differentially expressed protein spots from fresh CCB-
stained gels were excised and plated in 96-well microti-
tre plates. The excised spots were first destained twice
with 60 μl of 50 mM NH4HCO3 and 50% acetonitrile
and subsequently dried twice with 60 μl of acetonitrile.
The dried pieces of gel were then incubated in ice-cold
digestion solution (12.5 ng/μl trypsin and 20 mM
NH4HCO3) for 20 min and transferred into a 37°C incu-
bator for an overnight digestion. Finally, the peptides in
the supernatant were collected after being extracted
twice with 60 μl of the extraction solution (5% formic
acid in 50% acetonitrile).
The peptide solution described above was dried under
the protection of N2. A 0.8 μl aliquot of matrix solution
(5 mg/ml α-cyano-4-hydroxy-cinnamic acid diluted in
0.1% TFA, 50% ACN) was pipetted to dissolve it and
subsequently spotted onto a matrix-assisted laser de-
sorption ionisation (MALDI) target plate (Applied Bio-
systems). The MS analysis of the peptides was
performed using an ABI 4700 TOF-TOF Proteomics ap-
paratus (Applied Biosystems). The ultraviolet (UV) laser
was operated at a 200 Hz repetition rate with a wave-
length of 355 nm. The accelerated voltage was operated
at 20 kV, and the mass resolution was maximised at
1500 Da. Myoglobin digested with trypsin was used to
calibrate the mass instrument using the internal calibra-
tion mode. All the spectra acquired from the samples
were processed using 4700 ExploreTM Software (Ap-
plied Biosystems) in the default mode. The data were
searched using GPS Explorer (v3.6) with the search en-
gine MASCOT(2.1). The search parameters were as fol-
lows: the database, NCBInr; taxonomy, Viridiplantae
(green plants); the protein molecular mass, from 700 to
4000 Da; trypsin digestion with one missing cleavage;
MS tolerance, 100 ppm; and MS/MS tolerance, 0.6 Da.
Proteins with scores greater than 71 or a best ion score
(MS/MS) of more than 30 were considered to be signifi-
cant (P<0.05). This work was performed in collaboration
with the Proteome Research Center of Fudan University.
Typically, ten identities from one spot were provided,and the proteins of Gallus gallus (species) and the high-
est scores were selected according to the criteria for the
determination of proteins, as provided by the Proteome
Research Center of Fudan University.
Gene Ontology (GO) annotation using the Agbase
database
The proteins were analysed using the AgBase database
(http://www.agbase.msstate.edu). The list of accession
numbers was entered into GORetriever to return all
existing GO annotations available for that dataset. GOR-
etriever also provides a list of proteins without GO an-
notation and enters this second list into GOanna to
retrieve GO annotations assigned on the basis of se-
quence similarities. The resulting annotations were sum-
marised on the basis of the GOA whole proteome
GOSlim set using GOSlimViewer.
Protein functional interaction network analysis
The functional interaction networks of the proteins were
analysed using STRING (http://string.embl.de), which is
a database of known and predicted protein interactions
and includes direct (physical) and indirect (functional)
associations. The list of protein names was entered into
a table to provide the network of protein–protein inter-
actions. The Occurrence and Coexpression programs
provided the functional associations of the proteins.
Functionally associated proteins often have similar
phylogenetic profiles and/or display the phenomenon of
co-expression.
Real-time PCR
The expression levels of ANXA1, MIF, OP18, VIM and
NOM1 in the thymus of the chickens were determined
using real-time PCR (7500 Real-Time PCR System, ABI).
The sequences of the primers are provided in Table 2,
and the primer sequences for MIF, GAPDH and Meq
have been previously reported [72,73]. The primers were
synthesised by Shenergy Biocolor Bioscience & Technol-
ogy Company (Shanghai, China). Total RNA was pre-
pared from ground thymus tissue using the AxyPrep™
Multisource Total RNA Miniprep kit (AXYGEN, USA).
Total RNA (1 μg) was reverse transcribed into first-
strand cDNA using the PrimeScript RT Master Mix
(TaKaRa, USA) following the manufacturer’s instruc-
tions, and the synthesised cDNA was diluted 1:10 with
nuclease-free water. Diluted cDNA (1 μl), 400 nM pri-
mers and 10 μl of SYBR Green Master Mix were used
for the real-time PCR in a final volume of 20 μl. The
amplification conditions were: 95°C for 30 s, followed by
40 cycles of 95°C for 5 s, and 60°C for 34 s. Dissociation
curves were generated to analyse the individual PCR
products after 40 cycles. The expression levels of five
proteins were normalised against the expression of
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(GAPDH) mRNA. The analyses of the data for relative
gene expression were performed using the 2 –△△CT
method [74].
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